Melittin
Melittin, the principal pore forming peptide of honey bee (Apis mellifera) venom
Written by Aaron CuhaReviewed Sep 2026
Also known as: Bee venom peptide, Apis mellifera venom melittin
The main peptide in bee venom, about half its dry weight, and a non-selective membrane lytic toxin. Isolated melittin has never been tested for a therapeutic purpose in a human trial; whole bee venom has, in randomised trials of 26 to 538 people with mixed results and a documented anaphylaxis risk.
Overview
Melittin is a 26 amino acid peptide that makes up roughly half the dry weight of honey bee venom. It is a cationic, amphipathic molecule that inserts into cell membranes and opens pores, lysing cells without much regard for what kind they are. That property is why it is studied against cancer cells, viruses and bacteria, and why it cannot simply be injected: it destroys red blood cells and triggers mast cells to dump histamine. Nearly all serious research on melittin as a drug is about conjugates and nanoparticle carriers designed to keep it away from healthy membranes.
What has been measured in people needs careful separation. Isolated melittin has been given to humans in one published study that we could locate, a pain research paper from 2000 in which 5 mcg injected under the skin of the forearm caused severe transient pain and a sustained rise in skin temperature; it was used as a tool to cause pain, not to treat anything. No trial of isolated melittin for any therapeutic purpose is registered on ClinicalTrials.gov. Whole bee venom, which contains melittin alongside phospholipase A2, apamin, histamine and other components, has a real human trial literature, mostly from Korea and mostly as bee venom acupuncture: a 538 person randomised phase 3 of purified venom injected at acupuncture points for knee osteoarthritis reported a 1.1 point WOMAC pain advantage over a histamine control at 12 weeks (p = 0.001); a 54 person sham controlled trial in chronic low back pain reported improvement at 3 weeks; a 40 person randomised placebo controlled trial of monthly subcutaneous bee venom in Parkinson disease found no effect on motor scores or dopamine imaging over 11 months and excluded 4 patients for positive allergy skin tests; and a 26 person randomised crossover of live bee sting therapy in multiple sclerosis, up to 20 stings three times a week for 24 weeks, found no reduction in MRI lesions, relapses, disability or fatigue. A 2018 review in Toxicon notes that bee venom can cause anaphylaxis and that deaths have been reported in people who had previously tolerated the therapy. A phase 3 of a purified venom product for osteoarthritis (Apitox, NCT01112722, 363 participants) completed in 2016 with no results posted.
In cells and animals, melittin kills tumour cells, inactivates enveloped viruses and reduces inflammation markers in arthritis and neurodegeneration models, and melittin conjugates outperform free melittin on toxicity. Melittin is not approved anywhere for anything.
Mechanism of action
In people, the only direct measurement is the 2000 pain study: intradermal melittin produces immediate severe pain and a flare of increased skin temperature lasting over an hour, consistent with an axon reflex and mast cell activation, which lidocaine gel reduced the flare but not the pain. Everything else about melittin's action in humans is inferred from whole venom exposure, where melittin is one of several active components, and from the well documented consequences of bee stings: local pain, swelling, histamine release, and in sensitised people anaphylaxis. In vitro, melittin forms toroidal pores in lipid bilayers, causing leakage and lysis; it activates phospholipase A2, and at sub-lytic concentrations it modulates NF-kappaB and MAPK signalling, reduces inflammatory cytokine production and can trigger apoptosis in tumour cells. In rodents, free melittin causes haemolysis and is toxic at doses close to those that affect tumours, which is why the animal work has shifted to PEGylated, nanoparticle bound or antibody targeted forms. None of the mechanisms in this paragraph has been demonstrated in a human tissue in vivo.
Human evidence
For isolated melittin: one study, in which it was injected into forearms to cause pain. For whole bee venom, which is about half melittin: several randomised trials of 26 to 538 people with results ranging from a modest pain benefit in knee osteoarthritis to no effect in Parkinson disease and multiple sclerosis, plus a documented risk of anaphylaxis.
- Isolated melittin (2000): 5 mcg intradermally caused severe transient pain and a sustained skin flare in healthy volunteers. An experimental pain model, not a treatment.
- Whole venom, knee osteoarthritis (2019): 538 patients, 12 weekly sets of dermal injections versus histamine control. WOMAC pain 1.1 points better (p = 0.001), function 3.1 points better; injection site reactions under 5 percent.
- Whole venom, chronic low back pain (2017): 54 patients, sham controlled, improvement at 3 weeks on top of an NSAID.
- Whole venom, Parkinson disease (2016): 40 patients, monthly subcutaneous injections for 11 months, no effect on motor scores or dopamine imaging; 4 excluded for allergic sensitisation.
- Live bee stings, multiple sclerosis (2005): 26 patients, 24 weeks, no effect on MRI activity, relapses, disability or fatigue.
- Safety (2016 trial in 20 healthy adults): venom filtered of phospholipase A2 and histamine caused less local pain, swelling, itching and redness than unfiltered venom.
- Registered but unreported: Apitox phase 3 in osteoarthritis (NCT01112722), 363 participants, completed 2016, no results posted; Apitox phase 3 in multiple sclerosis (NCT03710655), status unknown.
- ClinicalTrials.gov, September 2026: no trial of isolated melittin for any therapeutic purpose.
What this does not tell you: None of the bee venom trials isolates melittin's contribution; venom contains phospholipase A2, apamin, histamine and other actives, and the Korean trials combine venom with acupuncture point stimulation. The largest positive trial used a histamine control that itself causes a local reaction, which helps blinding but is not an inert placebo, and a 1.1 point WOMAC pain difference is small. The two neurological trials were null. Nothing here supports any anticancer, antiviral or antimicrobial use of melittin in a person, all of which remain cell and animal findings. The anaphylaxis risk is real, cumulative exposure can sensitise people who were not allergic before, and the Parkinson trial had to remove 10 percent of participants for that reason.
Reading the research record
Melittin sits at the junction of two literatures that rarely talk to each other. The pharmacology literature treats it as a lead compound whose lytic power is the problem to be engineered around, which is why the recent papers are about nanoparticles, microneedles and conjugates, and why none of them involve people. The apitherapy literature treats bee venom as a traditional remedy and has run the human trials, almost all with whole venom, many in Korea where bee venom pharmacopuncture is an established practice, and a few in Europe where patients were already using bee stings for MS and Parkinson disease and academic groups tested whether it did anything. Those European trials were run by hospital and academic groups, not by anyone selling venom, and they were null.
The one large positive trial, 538 people with knee osteoarthritis, does not state its funding in the abstract and describes itself as a phase 3 of a purified venom product. Separately, Apimeds registered a phase 3 of its purified venom product Apitox in osteoarthritis that completed in 2016 with 363 participants and has never posted results. Whether the two are connected cannot be determined from the records; a positive published trial alongside an unreported registered one in the same indication is worth stating either way. What no one has funded is a trial of melittin itself, and the reason is pharmacological rather than economic: free melittin lyses red cells and degranulates mast cells at doses close to any therapeutic one, so there is no obvious safe way to give it systemically. Products sold as melittin or bee venom peptide for injection are selling a haemolytic toxin with a known anaphylaxis risk and no human therapeutic trial.
The evidence, charted
Fig. 1 · evidence composition
5of 8 citations (63%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 7 distinct years, 2000 to 2020, counted from the citation list on this page. The newest citation on file is from 2020, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Not approved
CA
Not approved
Approved in 1 of 4, prescription route in 0, not approved in 3. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Human2000
Computer-assisted infrared thermographic study of axon reflex induced by intradermal melittin
The only located human study of isolated melittin. 5 mcg injected intradermally into the forearm caused severe transient pain and a rise in skin temperature peaking at 10 minutes and lasting over an hour. Melittin was used as an experimental pain stimulus, not a treatment. Academic study, Japan.
Pain - Human2019
Efficacy and Safety of Honey Bee Venom (Apis mellifera) Dermal Injections to Treat Osteoarthritis Knee Pain and Physical Disability: A Randomized Controlled Trial
Whole purified venom, not melittin. 538 patients with knee osteoarthritis randomised 1:2 to histamine control or 100 mcg venom in 15 dermal injections at acupuncture points weekly for 12 weeks. WOMAC pain improved 1.1 points more than control (95% CI 0.3 to 2.0, p = 0.001) and physical function 3.1 points (p = 0.0046). Injection site reactions under 5 percent. Described as a phase 3; funding not stated in the abstract.
Journal of Alternative and Complementary Medicine - Human2016
Bee Venom for the Treatment of Parkinson Disease: A Randomized Controlled Clinical Trial
Whole venom. 40 patients with Parkinson disease randomised to monthly subcutaneous bee venom 100 mcg or saline for 11 months. No significant change in UPDRS III motor scores or dopamine transporter imaging. 4 patients excluded for positive allergy skin tests; no systemic allergic reaction. Academic trial, Paris hospitals (NCT01341431).
PLoS One - Human2005
A randomized crossover study of bee sting therapy for multiple sclerosis
Live bee stings, up to 20 per session three times weekly for 24 weeks, versus no treatment, in 26 people with relapsing MS. No reduction in new gadolinium enhancing MRI lesions, T2 lesion load, relapse rate, disability, fatigue or quality of life. No serious adverse events. Academic trial, Netherlands.
Neurology - Human2017
Efficacy of Bee Venom Acupuncture for Chronic Low Back Pain: A Randomized, Double-Blinded, Sham-Controlled Trial
54 patients with non-specific chronic low back pain, six sessions of real or sham bee venom acupuncture over 3 weeks on top of loxoprofen. Bothersomeness, pain intensity and function improved more in the venom group at 3 weeks; minimal adverse events in both groups. Korean academic funding.
Toxins - Review2018
To bee or not to bee: The potential efficacy and safety of bee venom acupuncture in humans
Review of bee venom acupuncture. Small studies report benefit in musculoskeletal and neurological conditions; bee venom can cause anaphylaxis and several deaths have been reported in patients who had previously received the therapy without incident. The incidence of adverse events is unknown.
Toxicon - Review2017
Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy
Review of preclinical anticancer work. Melittin shows activity in cell culture and animal models across many cancers, but non-specific cytotoxicity, degradation and haemolytic activity have prevented human use; nanoparticle and conjugate strategies are the response. NIH supported review.
Cancer Letters - Review2020
Melittin: a venom-derived peptide with promising anti-viral properties
Review of in vitro and animal antiviral studies covering coxsackievirus, influenza A, HIV, herpes simplex, RSV and others. The authors state that safety, routes of administration and mechanism need study before any clinical application.
European Journal of Clinical Microbiology and Infectious Diseases
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Bee venom therapy, using live stings or injected venom, has a long lay tradition for arthritis, multiple sclerosis and chronic pain; the 2005 MS trial was run because patients were already doing it, and the Parkinson trial used a standard allergy desensitisation dosing scheme for the same reason.
- The published Korean pharmacopuncture literature and the 2018 Toxicon review describe local pain, swelling, itching and redness at injection sites as routine, lasting hours to days, and worse with unfiltered venom.
- Allergic sensitisation with repeated exposure is documented in trials: 4 of 40 Parkinson patients developed positive skin tests during monthly injections and had to stop. The Toxicon review records anaphylaxis and several deaths in people who had previously tolerated the therapy.
- Cosmetic bee venom products are marketed for skin; no controlled human trial of a topical melittin product was located.
- Isolated melittin sold as a research peptide for injection has no documented human use pattern in any source we could find; what is known about injecting it comes from a single pain study in which 5 mcg caused severe pain.
Sources: The published apitherapy and bee venom acupuncture literature, including the Toxicon 2018 review, the Korean safety trial of filtered versus unfiltered venom, the recruitment rationale stated in the MS and Parkinson trials, and the registered Apitox trials. No forum or social media content was retrieved for this entry and nothing here is attributed to a specific post.
Frequently asked questions
Has melittin been tested in people?
As a treatment, no. The only published human study injected 5 mcg into the forearm to cause pain for a research model. Whole bee venom, which is about half melittin by weight, has been tested in randomised trials of 26 to 538 people, with a small pain benefit in knee osteoarthritis and low back pain and no effect in Parkinson disease or multiple sclerosis.
Does bee venom help arthritis?
In the largest trial, 538 people with knee osteoarthritis given weekly dermal venom injections for 12 weeks improved 1.1 points more on the WOMAC pain scale than a histamine control group. That is a statistically significant and modest effect in one trial whose funding is not stated. A separate registered phase 3 of a purified venom product completed in 2016 and has never reported.
Is melittin an anticancer or antiviral drug?
In cells and animals it kills tumour cells and inactivates several viruses, and reviews of that work exist. No person has received melittin for cancer or a viral infection in a trial, and the reason is that free melittin destroys red blood cells and activates mast cells at doses close to the ones that would be needed.
What is the risk of injecting bee venom or melittin?
Local pain and swelling are routine. Repeated exposure can sensitise people who were not allergic, as happened to 4 of 40 patients in the Parkinson trial. Anaphylaxis, including deaths in people who had previously tolerated venom therapy, is documented in the review literature. Isolated melittin at 5 mcg caused severe pain in the one human study.